Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Amyloid-beta (Aβ) N-terminal epitope refers to the amino-terminal sequence of the Aβ peptide, typically encompassing residues 1 through 16, which is generated by the proteolytic cleavage of the amyloid precursor protein (APP) (Miles et al., 2011; DOI: 10.1038/srep00131). This region is highly accessible and serves as a primary target for passive immunotherapy in Alzheimer's disease because it remains exposed across various Aβ species, including soluble oligomers and insoluble fibrils (Sevigny et al., 2016; DOI: 10.1038/nature19323). Monoclonal antibodies such as aducanumab and lecanemab bind to this epitope to facilitate the clearance of amyloid plaques from the brain, primarily through microglial-mediated phagocytosis (van Dyck et al., 2023; DOI: 10.1056/NEJMoa2212948). Some therapies, like donanemab, specifically target post-translationally modified versions of this epitope, such as N-terminal pyroglutamate (pGlu3-Aβ), which is found exclusively in aggregated plaques (Mintun et al., 2021; DOI: 10.1056/NEJMoa2100708). By reducing the accumulation of these toxic aggregates, these therapies aim to slow cognitive decline and preserve neurological function in patients with early-stage Alzheimer's disease. However, targeting the N-terminus is frequently associated with Amyloid-Related Imaging Abnormalities (ARIA), which include brain edema (ARIA-E) and microhemorrhages (ARIA-H), requiring careful clinical monitoring (Sperling et al., 2011; DOI: 10.1016/j.jalz.2011.05.2351).
Monoclonal antibodies bind to the N-terminal epitope of amyloid-beta (Aβ) peptides, which facilitates the clearance of existing amyloid plaques via Fc-receptor-mediated microglial phagocytosis and prevents the further aggregation of soluble Aβ monomers into neurotoxic oligomers and fibrils (Sevigny et al., 2016; DOI: 10.1038/nature19323; van Dyck et al., 2023; DOI: 10.1056/NEJMoa2212948).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amyloid-beta protein N-terminal epitope (Aβ N-terminal epitope).